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OBJECTIVE: To determine whether there is any influence of systemic arterial hypertension on the peripheral
auditory system.
METHODS: This was a cross-sectional study that investigated 40 individuals between 30 and 50 years old, who
were divided into groups with and without systemic arterial hypertension, using data from high-frequency
audiometry, transient-evoked otoacoustic emissions and distortion-product otoacoustic emissions. The results
were compared with those from groups of normal-hearing individuals, with and without systemic arterial
hypertension, who underwent the pure-tone audiometry test. All individuals also underwent the following
procedures: otoscopy, acoustic immittance measures, pure-tone audiometry at frequencies from 250 to 16000
Hz, transient-evoked otoacoustic emissions test and distortion-product otoacoustic emissions test.
RESULTS: No statistically significant difference was observed between the groups with and without systemic
arterial hypertension in either conventional or high-frequency audiometry. Regarding transient-evoked
otoacoustic emissions, there was a trend toward statistical significance whereby the systemic arterial
hypertension group showed lower results. Regarding distortion-product otoacoustic emissions, the systemic
arterial hypertension group showed significantly lower results at the following frequencies: 1501, 2002, and
3003 Hz. A discriminant analysis indicated that the distortion-product otoacoustic emissions variables best
distinguished individuals with and without systemic arterial hypertension.
CONCLUSION: Data from this study suggest cochlear dysfunction in individuals with systemic arterial hypertension
because their otoacoustic emission results were lower than those in the systemic arterial hypertension group.
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’ INTRODUCTION
Although systemic arterial hypertension (SAH) is a silent
disease, some individuals experience headaches, dizziness,
tinnitus, chest pain, and weakness associated with the
condition. In addition, SAH may involve secondary hearing
changes (1,2).
Diseases that affect the circulatory system can affect the
inner ear in many ways (3) as living cells require an adequate
supply of oxygen and nutrients to function, and this provision
depends on the integrity of the heart and blood vessels (4,5).
It is also believed that presbycusis may be potentiated by
hyperviscosity syndrome or microangiopathy caused by
diabetes or SAH associated with microcirculatory failure due
to vascular occlusion secondary to embolism, hemorrhage, or
vasospasm. SAH could thus occur because these factors
cause or potentiate hearing loss (6).
Current studies in the literature are controversial regard-
ing whether SAH affects the peripheral auditory system (7).
Some studies have revealed a positive association between
SAH and hearing loss (5,8-10). However, other studies failed
to observe this relationship (11,12). No study has used
various methods of peripheral auditory system evaluation
simultaneously in individuals with SAH, which demon-
strates the importance of this research. The use of other
audiological procedures in addition to conventional audio-
metry can provide earlier and more accurate indications of
possible cochlear changes resulting from SAH, which can
help preserve the hearing of affected individuals.
The hypothesis of this study is that hypertensive adults
with normal hearing, according to conventional audiometry,
will exhibit differences in the results of high-frequency
audiometry, Transient evoked otoacoustic emissions (TEOAE)DOI: 10.6061/clinics/2016(04)02
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and Distortion product otoacoustic emissions (DPOAE) com-
pared with individuals without SAH.
’ METHODS
Subjects
A survey was conducted on the medical records of
patients treated at the Hospital Universitário da Universi-
dade de São Paulo-HU-USP from 2009-2012. The following
inclusion criteria were used: age between 30 and 50 years;
normal hearing detected by conventional audiometry
(thresholds p25 dBNA); absence of obstruction of the
external auditory canal or middle ear disorders; absence of
diagnosed metabolic diseases; and no history of noise
exposure.
A total of 40 subjects participated:
- Twenty patients, 13 women and seven men aged 31-48
years, (mean±SD 41.4±5.9) with SAH who were diag-
nosed from one to 23 years previously (mean 7.75).
Hypertension was defined as a systolic blood pressure
X140 mmHg or diastolic blood pressure X90 mmHg. The
participants were being treated with angiotensin receptor
antagonists (nine patients), inhibitors of angiotensin-con-
verting enzymes (five patients), beta-blockers (one patient),
calcium channel blockers (one patient), or a thiazide
diuretic only (one patient). Three participants were not
prescribed any medication for SAH.
- Twenty patients, 13 women and seven men aged 35-50 years,
(mean±standard deviation, 45.5±4.7) without SAH.
Ethical Considerations
The protocol was approved by the Research Ethics
Committee of the institution (n1065/10) and informed consent
was obtained prior to participation.
Procedures
The participants underwent an interview to confirm their
medical and otological history. The following procedures were
then performed:
- Acoustic immittance measurements (tympanometry, acous-
tic reflex) (AT 235, Interacoustic).
- Pure tone audiometry from 250 to 16,000 Hz (Itera II,
Madsen).
- TEOAE (ILO-92, Otodynamics). Cochlear responses were
analyzed in the 1,000-5,000 Hz frequency range using a
click stimulus at 84 dBpeSPL. Emissions occurred when the
following parameters were observed: reproducibility
greater than 50%, probe stability greater than 75% and a
signal/noise ratio X3 dB for four or five of the evaluated
frequency bands (1, 2, 3, 4 and 5 kHz).
- DPOAE (ILO-92, Otodynamics). Two different paired
frequencies (f1 and f2, being f2/f1 = 1,2) were presented at
an intensity of 65dB (f1) and 55dB (f2). Responses occurred
when the signal/noise ratio was X3 dB relative to the
second standard deviation of background noise for five or
more of the f2 frequencies (1001, 1501, 2002, 3003, 4004, 5005
and 6006 Hz).
All audiological tests were performed in a soundproof
booth.
Statistical analyses were performed using the Hotelling
T2 multivariate test to evaluate possible differences between
the right and left ears in the measured variables. Thereafter,
repeated measures models were adjusted for each of the
variables based on a "standard profile", such that the cor-
relation between measurements of the same patient could be
incorporated and an expected value was calculated for a
particular response. Fisher’s exact test and the discriminant




The hearing thresholds of the two groups are shown in
Figure 1. There was no statistically significant difference
between ears when comparing conventional and high-
frequency audiometry (Hotelling’s T2 test - p-value=0.54).
Thus, for this analysis, the standard profile was that of a
43-year-old woman without SAH (Table 1). Regarding age,
we noted that there was a statistically significant difference for
some frequencies, e.g., increasing age by one year increased
the mean threshold. Regarding gender, there was a significant
difference only at 4000 Hz, with males exhibiting higher
values. There was no statistically significant difference in the
between-groups comparison. However, hearing thresholds at
3 kHz in the SAH group were higher than those in the group
without SAH.
’ TEOAE
There was a statistically significant difference in the
comparison between ears (p=0.006, Hotelling’s T2 test).
Therefore, the adopted standard profile referred to the left
ear of a 43-year-old woman without SAH (Table 2). Regarding
gender, there was a statistically significant difference in the
amplitude and reproducibility variables, with men exhibiting
lower mean values. Although the SAH group had lower
values for TEOAE amplitudes, there was no significant
difference between the groups. Regarding the comparison
between ears, the right ear showed higher values for most
variables.
Regarding the absence of TEOAE, 45% (9 ears) of the ears
had absent emissions in the SAH group, whereas 35% of the
ears (7 ears) in the group without SAH had absent responses
(p=0.358 - Fisher’s exact test).
Figure 1 - The average of the hearing thresholds of 20 patients




Soares MA et al.
CLINICS 2016;71(4):187-192
’ DPOAE
There was no statistically significant difference between
the ears (p=0.43, Hotelling’s T2 test). Thus, the standard
profile was a 43-year-old woman without SAH (Table 3).
A statistically significant difference in DPOAE amplitudes at
1501, 2002 and 3003 Hz was observed between the groups,
with the SAH group exhibiting lower values.
Regarding the absence of DPOAE, we observed that in the
SAH group, 5% of the ears (one ear) had absent emissions
(at frequencies of 1501, 2002, 3003, 4004, 5005 and 6006 Hz),
whereas no ears in the group without SAH had absent
responses (p=0.246, Fisher’s exact test).
Discriminant analysis
A discriminant analysis was performed to verify whether
the analyzed variables could form a linear function capable
of classifying patients into groups with and without SAH.
This analysis enabled us to investigate which variables could
most accurately predict the group to which a particular
individual belonged (with or without SAH). Table 4 shows
that the highest percentage of the correct score of discrimi-
nant analysis is 60% for TEOAE and DPOAE when
the classification is made for the two groups simultaneously
(e.g., using the results of TEOAE and DPOAE, 60% of the
individuals with SAH and 60% of the individuals without
SAH were correctly classified within their respective group).
’ DISCUSSION
The mean disease duration of the hypertensive group was
7.75 years. Esparza et al. (1) studied a group with four years ago
of disease diagnosis (on average). Agarwal et al. (8) evaluated
three groups divided into different grades of SAH and the mean
disease duration ranged from 3.7 to 9.0 years. The difference in
the duration of the SAH observed in these studies may
influence the audiological results obtained when we consider
the length of time that the microcirculatory impairment was
present, which may be a variable that affects the deterioration of
the peripheral auditory system to some extent (6).
In the group with SAH, three individuals were not taking
any medication for SAH. The presence of associated
cardiovascular risk factors, in addition to blood pressure
values, should be accounted for when making therapeutic
decisions regarding the use of medication. Patients with mild
SAH and no other comorbidities may initially be prescribed
lifestyle changes (13).
Table 1 - Estimates and p-values of the model effects of the audiometry variables.
dBNA estimate (p-value)
Variable Estimate for standard profile Estimate for age (each year) Estimate for male gender Estimate for SAH group
250 Hz 8.05 (o0.001)* -0.12 (0.235) -0.18 (0.876) 0.01 (0.99)
500 Hz 7.13 (o0.001)* -0.05 (0.662) -2.49 (0.084)** 1.11 (0.446)
1000 Hz 7.09 (o0.001)* 0.07 (0.584) -2.36 (0.092) 1.22 (0.389)
2000 Hz 6.01 (o0.001)* -0.06 (0.636) -1.42 (0.283) 0.86 (0.545)
3000 Hz 6.17 (o0.001)* 0.07 (0.628) 2.42 (0.126) -0.78 (0.624)
4000 Hz 9.18 (o0.001)* 0.08 (0.577) 3.16 (0.05)* -0.08 (0.961)
6000 Hz 11.45 (o0.001)* 0.21 (0.172) 0.67 (0.691) -1.13 (0.516)
8000 Hz 8.63 (o0.001)* 0.04 (0.794) -0.11 (0.954) -0.44 (0.825)
9000 Hz 14.22 (o0.001)* 0.01 (0.969) 2.99 (0.213) -2.28 (0.352)
10.000 Hz 15.25 (o0.001)* 0.19 (0.455) 3.95 (0.156) -0.27 (0.922)
11.200 Hz 19.92 (o0.001)* 0.60 (0.059)** 3.80 (0.271) -1.61 (0.645)
12.500 Hz 18.81 (o0.001)* 1.08 (0.009)* 5.19 (0.238) -2.74 (0.539)
14.000 Hz 29.87 (o0.001)* 1.86 (o 0.001)* 4.60 (0.365) -7.95 (0.130)
16.000 Hz 39.70 (o0.001)* 1.94 (o 0.001)* 2.00 (0.641) -3.17 (0.472)
*= statistically significant; ** = marginal p-value (tendency toward statistical significance).
Table 2 - Estimates and p-values of the adjusted repeated measures model effects of the transient-evoked otoacoustic emission
variables.
dB Estimate (p-value)
Variable Estimate for standard
profile










13.82 (o0.001)* 0.13 (0.254) -2.73 (0.031)* -1.81 (0.154) 1.60 (0.003)
Reproducibility 89.65 (o0.001)* 0.19 (0.453) -6.25 (0.031)* -5.17 (0.078)** 2.72 (0.067)**
1 kHz (%) 85.20 (o0.001)* -0.18 (0.713) 5.42 (0.323) -7.64 (0.177) 4.55 (0.001)*
2 kHz (%) 90.85 (o0.001)* 0.23 (0.488) -4.67 (0.203) -3.37 (0.367) 3.77 (0.200)
3 kHz (%) 83.95 (o0.001)* 0.35 (0.636) -18.33 (0.028)* 2.93 (0.723) -3.17 (0.423)
4 kHz (%) 73.95 (o0.001)* -0.43 (0.556) -25.97 (0.003)* 0.83 (0.921) 5.32 (0.175)
5 kHz (%) 43.90 (o0.001)* -0.53 (0.515) -19.81 (0.031)* 3.26 (0.721) 12.57(0.067)**
1 kHz (dB) 9.71 (o0.001)* 0.03 (0.843) 1.30 (0.427) -2.82 (0.097)** 2.30 (0.001)*
2 kHz (dB) 12.67 (o0.001)* 0.23 (0.092)** -2.25 (0.135) -2.31 (0.135) 1.95 (0.037)*
3 kHz (dB) 10.32 (o0.001)* 0.22 (0.164) -3.85 (0.028)* -1.15 (0.509) -0.60 (0.441)
4 kHz (dB) 7.68 (o0.001)* -0.08 (0.577) -5.30 (0.001)* -1.25 (0.430) 0.52 (0.491)
5 kHz (dB) 1.96 (0.061)** -0.08 (0.455) -2.11 (0.072)** 0.30 (0.800) 1.17 (0.237)
* = statistically significant difference; ** = marginal p-value (tendency toward statistical significance).
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Among the treated patients, only one patient used thiazide
diuretics, whereas the others used SAH medication, some of
which were associated with diuretics. Of the 16 subjects who
used SAH medication, only five were associated with the use
of diuretics. Both monotherapy and combination therapy
may be effective for controlling blood pressure, and a
decision regarding therapy type should be made for each
case according to the clinical scenario (14).
Thiazide diuretics are most often used to combat SAH (14).
There are studies (15) that emphasize the risk of loop diuretics
for hearing, but we did not find any references regarding the
ototoxicity of thiazide diuretics in hypertensive adults.
Regarding the use of specific antihypertensive drugs,
we found only one case study that correlated the use of
beta-blocking drugs with the occurrence of mixed hearing
loss (16). Furthermore, only one participant was using a
beta-blocker. Esparza et al. (1) stated that the possible
deleterious effects of some antihypertensive drugs on
cochlear function remain inconclusive because there are no
follow-up studies of cochlear function in patients who use
this medication.
Regarding audiometry, we observed no statistically signi-
ficant differences between ears. The literature is consistent
regarding the absence of differences between the hearing
thresholds in conventional audiometry and those in high-
frequency audiometry in the left and right ears (17).
When analyzing the audiometry data, we observed a
significant age effect for some frequencies. This effect has been
previously described in other studies, which suggest that
auditory thresholds worsen with increasing age (18). Regarding
the gender variable, the mean hearing threshold value was
significantly greater in men at one frequency (17,19). Addition-
ally, for other frequencies evaluated in conventional audiometry
and at high frequencies, men had slightly worse hearing
thresholds than women (from 3000 Hz). Many studies have
reported this difference in hearing thresholds between genders
and have mainly attributed this more evident hearing loss in
men to lifestyle as men tend to be more exposed to noise (20,21).
We observed no statistically significant differences in
audiometry results between the groups. However, starting
at a frequency of 3 kHz, the SAH group had worse hearing
thresholds.
Many studies have used conventional audiometry to
compare individuals with and without SAH. Our results
relative to conventional audiometry corroborate the results
of Mondelli and Lopes (2) and Wu et al. (22) but disagree
with the studies of Esparza et al. (1), Sahin-Yilmaz et al. (23)
and Agarwal et al. (8), who observed obvious differences in
conventional audiometry thresholds between groups with
and without SAH.
Regarding high-frequency audiometry, no studies were
observed in the literature that used this method to compare
groups with and without SAH. However, we must consider
that the number of individuals in the two groups was small
and perhaps the small differences in the frequencies above
8 kHz would be more evident with a larger sample size.
Regarding the TEOAE, we observed statistically signifi-
cant differences in amplitudes between the ears and the
responses for the right ear were better in general, which has
been previously reported in the literature (24).
In the TEOAE analysis, we observed no significant effect of
age, but there was a significant difference for gender, with a
lower mean response value for males. Other authors have also
reported significant differences in otoacoustic emissions bet-
ween genders, with a greater amplitude of TEOAE responses in
females (24).
When comparing the TEOAE results between the groups,
we observed a trend toward statistical significance for the
overall reproducibility and amplitude at a frequency of
1 kHz, with lower values in the SAH group. No studies were
found in the literature comparing groups with and without
SAH using the TEOAE. However, when analyzing the results
obtained by audiometry and TEOAE, we can suggest that
the second method is more sensitive in detecting possible
cochlear changes in hypertensive subjects than the first
method. This finding corroborates the literature that indi-
cates that OAE are more sensitive in identifying cochlear
changes before they can be observed on an audiogram (15).
The cochlear passive mechanism, described by Békésy,
demonstrated the tonotopy of the cochlea. However, it did
not explain how this process takes place in live cochlea. The
emergence of OAE led to the search for knowledge regarding
cochlear active mechanisms. Otoacoustic emissions (TEOAE
or DPOAE) occur as a by-product of cochlear mechanisms
(15). The recording of OAE enables evaluation of the integrity
of outer hair cells, which are considered effectors in the
cochlear amplification mechanism due to its biomechanical
Table 3 - Estimates and p-values of the adjusted repeated measures model effects of DPOAE variables.
dB Estimate (p-value)
Variable Estimate for standard profile Estimate for age (each year) Estimate for male gender Estimate for SAH group
1001 Hz 15.31 (o0.001)* 0.02 (0.913) 2.78 (0.192) -1.73 (0.425)
1501 Hz 22.74 (o0.001)* 0.07 (0.672) 2.10 (0.290) -6.49 (0.003)*
2002 Hz 20.04 (o0.001)* 0.04 (0.829) 0.05 (0.982) -5.04 (0.040)*
3003 Hz 19.03 (o0.001)* 0.10 (0.527) -1.66 (0.341) -3.90 (0.033)*
4004 Hz 20.16 (o0.001)* -0.15 (0.228) -1.75 (0.212) -1.31 (0.360)
5005 Hz 21.51 (o0.001)* -0.23 (0.174) -1.28 (0.484) -1.74 (0.358)
6006 Hz 14.50 (o0.001)* -0.15 (0.512) -2.26 (0.362) -1.71 (0.498)
*= statistically significant difference; ** = marginal p-value (tendency toward statistical significance).
Table 4 - The percentage of correct scores in the discriminant
analysis for both ears combined.
Correct score
Variables Without SAH With SAH Total
Audiometry 47.5% 42.5% 45.0%
TEOAE (Amplitude and Repro) 52.5% 65.0% 58.7%
TEOAE (Other variables) 62.5% 57.5% 60.0%
DPOAE 65.0% 55.0% 60.0%
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properties. Its electric mobility enables the inner hair cells,
which are essentially sensory, to perform the transduction
process. The integrity of the stria vascularis (25) plays an
important role in the mechanism of evoked otoacoustic
emissions. The stria vascularis has a function in maintaining
vital electrochemical gradients for the activity of outer hair
cells. Changes in this structure could potentially be related to
the reduction response of OAE.
We observed no effect of ear, age, or gender on DPOAE.
There were statistically significant differences only in the
comparison of DPOAE amplitudes at 1501, 2002 and 3003 Hz
between the groups with and without SAH, with lower
responses found in the SAH group.
The differences found in DPOAE between the groups with
SAH and without SAH are consistent with the study of Sahin-
Yilmaz et al. (23), which revealed a smaller number of
subjects with DPOAE in the SAH group. In the present study,
we found a small difference between the numbers of subjects
with DPOAE. However, the smaller DPOAE amplitude in the
group with SAH is indicative of cochlear impairment.
Other studies using DPOAE to evaluate individuals with
SAH and cardiovascular disease also emphasized the deleter-
ious effect of these disorders on inner ear function (1,7,26).
This procedure has also been used successfully to monitor
cochlear function in patients exposed to ototoxic agents
(27,28) and we thus suggest that DPOAE should also be used
as a complementary evaluation of cochlear function in
hypertensive patients.
A qualitative analysis of OAE showed that for TEOAE,
more absent responses were obtained in the SAH group (45%
versus 35% in the group without SAH), and for DPOAE,
absent responses occurred only in the group with SAH (5%).
TEOAE are more sensitive to cochlear changes and
DPOAE are less sensitive to sub-clinical conditions in adults.
Thus, small cochlear changes can affect TEOAE more
"quickly" than DPOAE (15), which may explain the higher
number of absences in the TEOAE than the DPOAE in both
groups. It should also be emphasized that hypertension was
not the only variable that may have influenced the OAE
results. For instance, because both groups were comprised of
30- to 50-year-old individuals, age may also have acted as an
influencing factor on OAE responses because there is a
decrease in cochlear function with increasing age.
Therefore, in addition to SAH, such potential covariates (e.g.,
age, gender) may influence the number of present and absent
responses and the amplitude of the OAE responses. Because
TEOAE are more sensitive, we hypothesize that the influence of
these covariates on this type of emission will soon be observed
and is thus unlikely to allow for the precise identification of
differences between the groups with and without SAH.
Moreover, because DPOAE are less sensitive, even with
influences from uncontrolled covariates, DPOAE offer a greater
possibility to detect differences that arise from SAH.
The discriminant analysis indicated higher percentages of
correct scores for OAE than audiometry, suggesting that
OAE was the audiological evaluation that allowed the
differentiation of individuals with and without SAH.
Furthermore, based on the results of the discriminant
analysis combined with those of the quantitative analyses,
we can suggest that DPOAE in general is the best method for
classifying individuals within groups with or without SAH.
Although the TEOAE and DPOAE techniques are com-
plementary, DPOAE is more suitable for advanced clinical
investigation in adult patients because it is more flexible and
allows for a more precise analysis than TEOAE (15).
According to our results, DPOAE is also indicated in the
evaluation of hypertensive adults.
It is important to mention that the present study was based
on a small sample. We therefore suggest that future studies
should be conducted with a larger number of hypertensive
individuals. Furthermore, longitudinal studies of hearing in
individuals with this condition may contribute significantly
to the identification of the effect of SAH on hearing.
Because the individuals who participated in this research
had hearing thresholds within normal conventional audio-
metry limits, had no history of exposure to noise or other
metabolic diseases and had their statistical analyses
adjusted for possible influences arising from gender or
age, we consider that the differences observed between the
procedures (high-frequency audiometry, TEOAE and
DPOAE) between hypertensive and non-hypertensive
patients, regardless of significance, could be related to
the presence or absence of this condition, which can cause
bleeding in the inner ear (4,29,30) and microcirculatory
failure (6).
Thus, although controversy remains regarding the influence
of SAH on hearing, it is necessary to closely investigate hyper-
tensive patients, who must undergo audiological monitoring
that includes not only conventional but also high-frequency
audiometry and/or otoacoustic emission testing that can
identify possible cochlear malfunctions earlier.
The differences observed between hypertensive and non-
hypertensive patients using various procedures allowed us
to suggest that hypertensive individuals have cochlear
dysfunction that is not detected by conventional audiometry.
Furthermore, the most sensitive tool for discrimination
between individuals with and without SAH was DPOAE,
rather than high-frequency audiometry and TEOAE.
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